Pilar Lopez Santi

Dr. Pilar Lopez Santi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
PDF file
SGSebastian Garcia-Zamora
Sebastian Garcia-Zamora
PIPablo A. Iomini
Pablo A. Iomini
LPLaura Pulido
Laura Pulido
AMAndrés F. Miranda-Arboleda
Andrés F. Miranda-Arboleda
PSPilar Lopez Santi
Pilar Lopez Santi
ABAdrian Marco Baranchuk
Adrian Marco Baranchuk
Objetivos. Explorar la frecuencia e impacto de la violencia contra los trabajadores de salud de Argentina y compararlo con el resto de sus pares de Latinoamérica en el contexto de la pandemia por COVID-19. Materiales y métodos. Estudio de corte transversal a través de una encuesta electrónica al personal médico y no médico de Latinoamérica que desempeño tareas asistenciales desde marzo de 2020. Se utilizó una regresión de Poisson para estimar las Razones de Prevalencia crudas (RP) y ajustadas (RPa) con sus respectivos intervalos de confianza al 95%. Resultados. Un total de 3544 participantes de 19 países respondieron la encuesta; 1992 (56,0%) residían en Argentina. Entre los mismos, el 62,9% padeció al menos un hecho de violencia: 97,7% refirió violencia verbal y 11,8% violencia física. El 41,5% de los agredidos padecieron situaciones de violencia al menos una vez por semana. El personal de salud de Argentina vivenció más frecuentemente violencia que los de otros países (62,9% vs. 54,6%, p<0,001), siendo estos eventos más habituales y estresantes (p<0,05). Además, refirieron más frecuentemente haber considerado cambiar sus tareas asistenciales y/o deseos de abandonar su profesión (p<0,001). En la regresión de Poisson, los participantes deArgentina tuvieron una prevalencia de violencia mayor que los trabajadores de salud de la región (14,6%; p<0,001). Conclusiones. Existió una elevada prevalencia de violencia contra el personal de salud de Argentina durante la pandemia por COVID-19. Estos hechos tuvieron un alto impacto negativo entre quienes los padecieron. Nuestros datos sugieren que, esto podría haber sido más frecuente en Argentina respecto de otras regiones del continente.

5 June 2025 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PSPilar Lopez Santi
Pilar Lopez Santi
JBJeremy Bernard
Jeremy Bernard
FFFederico Fortuni
Federico Fortuni
SBSteele C Butcher
Steele C Butcher
MMMaria Chiara Meucci
Maria Chiara Meucci
Nina Ajmone MarsanNina Ajmone Marsan
Nina Ajmone Marsan
Aims: Left ventricular (LV) dilatation is an important prognostic factor in patients with aortic regurgitation (AR). Although current guidelines recommend the use of LV end-systolic diameter index (LVESDi) to indicate the need for intervention, recent studies suggested that LV end-systolic volume index (LVESVi) may more accurately characterize LV remodelling. The present study aims to evaluate, in a multi-centre setting, whether combining LV linear and volumetric measures could improve risk stratification. Methods and results: A total of 1070 patients (56 ± 18 years, 65% male) with significant AR were included. Cut-off values of 20 mm/m2 for LVESDi and 45 mL/m2 for LVESVi were used to identify the following groups: no-significant LV dilatation (n = 485), when both LVESDi and LVESVi were below the cut-off values; discordant LV dilatation (n = 279) if only one positive criterium was present; and concordant LV dilatation (n = 306) when both LVESDi and LVESVi were enlarged. The primary endpoint was all-cause mortality. During a median follow-up of 7.4 (IQR, 4.5–11) years, 168 patients (16%) died, and 484 (45%) underwent aortic valve surgery (AVS). Patients with concordant LV dilatation showed the worst 10-year survival (P < 0.001). Discordant (HR 2.066, 95% CI 1.295–3.298; P = 0.002) or concordant LV dilatation (HR 2.759, 95% CI 1.616–4.710; P < 0.001) was independently associated with higher mortality compared with patients with no-significant LV dilatation after adjusting for relevant clinical and echocardiographic variables and regardless of AR severity. However, both groups showed greater benefit from AVS. LV dilatation, either concordant or discordant, was also independently associated with outcome in asymptomatic patients and those with left ventricular ejection fraction > 55%. Conclusion: In patients with significant AR, the presence of LV dilatation detected by linear and/or volumetric measures was independently associated with increased mortality.

29 September 2023 in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
Verified
Journal Article
Open access
PDF file
ASAlan R. Sigal
Alan R. Sigal
BCBraian Abel Cardinali-Re
Braian Abel Cardinali-Re
LCLucas Campana
Lucas Campana
PSPilar Lopez Santi
Pilar Lopez Santi
PIPablo Iomini
Pablo Iomini
(C(Conarec) Consejo Argentino de Residentes de Cardiología
(Conarec) Consejo Argentino de Residentes de Cardiología
Objective. To evaluate the self-perception of cardiology residents in Argentina regarding their abilities to help their patients stop smoking, as well as their opinions about their knowledge and skills in this area. Materials and methods. A cross-sectional study was carried out using secondary data from a study carried out in five Latin American countries and Spain, focusing on the information provided by cardiology residents in Argentina. Discrete variables were expressed as median and interquartile range, and categorical variables were expressed as percentages, and were analyzed using the chi-square test or Fisher’s exact test, depending on the relative frequency of the expected values. Results. 447 residents participated; 87.5% routinely provided brief advice to quit smoking, and 11.6% used validated questionnaires to assess the degree of addiction. Furthermore, 32.1% stated that they prescribed pharmacological treatment, but 53.1% were only familiar with a single drug. When asked about their self-perception of getting their patients to stop smoking, the median response was 5 (scale from 1 to 10); only 13.7% responded with a score of 8 or more. Conclusions. The present study suggests that cardiology residents in Argentina recognize the importance of carrying out smoking cessation interventions, but a high proportion of them do not feel qualified to do so.

17 October 2025 in European Heart Journal
Verified
Journal Article
Closed access
PSPilar Lopez Santi
Pilar Lopez Santi
JBJérémy Bernard
Jérémy Bernard
ACAileen Chua
Aileen Chua
DLDorien Laenens
Dorien Laenens
APAndréanne Powers
Andréanne Powers
Nina Ajmone MarsanNina Ajmone Marsan
Nina Ajmone Marsan
Background and Aims: There are limited data on mortality in patients with moderate mixed aortic valve disease (MAVD), defined as the combination of moderate aortic stenosis (AS) and moderate aortic regurgitation (AR). Consequently, current guidelines lack specific recommendations for aortic valve replacement (AVR) in this population. This study aims to compare survival between moderate MAVD and isolated severe AS or severe AR, and to evaluate the impact of symptoms or left ventricular ejection fraction (LVEF) < 50%, as current criteria for AVR in severe AS or AR. Methods: Overall, 1926 patients were included from four centers: 527 with moderate MAVD, 413 with severe AR, and 986 with severe AS. The primary endpoint was all-cause mortality. Results: Over a median follow-up of 7.2 (interquartile range 3.4–11.3) years, 748 patients died. After adjusting for clinical and echocardiographic variables (including New York Heart Association [NYHA] class, LVEF < 50%, and AVR as time-dependent covariate), moderate MAVD patients showed 10-year survival similar to severe AS but worse than severe AR (62%, 55%, and 79%, respectively; P < .001). Symptomatic moderate MAVD patients showed adjusted mortality comparable to symptomatic severe AS, while asymptomatic moderate MAVD patients had adjusted mortality similar to severe AR (symptomatic and asymptomatic). Moderate MAVD patients with LVEF < 50% had adjusted mortality comparable to severe AS with LVEF < 50%, while those with LVEF ≥ 50% showed mortality similar to severe AR (regardless of left ventricular dysfunction). Conclusions: In moderate MAVD, the presence of symptoms or LVEF < 50% is associated with increased mortality, comparable to isolated severe AS under similar conditions. Therefore, patients with moderate MAVD should benefit from AVR in the presence of symptoms or left ventricular dysfunction.

5 December 2025 in Global Heart
Verified
Journal Article
Open access
PDF file
Fernando Stuardo WyssFernando Stuardo Wyss
Fernando Stuardo Wyss
RLRicardo Lopez
Ricardo Lopez
DPDaniel Piskorz
Daniel Piskorz
HGHoracio Márquez Gonzalez
Horacio Márquez Gonzalez
LGLucelli Yañez Gutierrez
Lucelli Yañez Gutierrez
OIOn Behalf of The CorVacc Study investigators
On Behalf of The CorVacc Study investigators
Introduction: Immunization rates against influenza and pneumococcus in Latin America remain lower than expected, particularly in Andean region, Central America, Mexico, and Caribbean region. An incremental correlation between economic strata and educational level and vaccines uptake has been observed. This highlights the need for more comprehensive data to accurately characterize the current health landscape and develop strategies for improvement. Methods and Design: The Inter-American Registry of Influenza and Pneumococcal Vaccination (CorVacc Study) is a cross-sectional survey of the general population conducted across 19 Latin American countries. Adults aged 18 years and older completed a 34-question online survey. The pool was validated within the first 1000 responses. Data were grouped into seven categories: demographics, socioeconomic and educational level, cardiometabolic profile, cardiovascular interventions, medical follow-up and treatments, and COVID-19 vaccination status. Results: A total of 21,389 responses were obtained, distributed as follows: 8915 from the North, Central, and Caribbean region; 7492 from the Andean region; and 4801 from the Southern Cone region. Influenza vaccination rates were lower in the Andean region (OR: 0.62; 95% CI: 0.50–0.78), the Caribbean (OR: 0.30; 95% CI: 0.23–0.39), and Central America (OR: 0.59; 95% CI: 0.46–0.76) compared with the Southern Cone. Residing in Central America (OR: 3.06; 95% CI: 1.62–5.77) was associated with greater pneumococcal vaccination. The probability of being vaccinated against influenza was higher in men (OR: 1.3; 95% CI: 1.1–1.6) and in individuals with obesity (OR: 1.26; 95% CI: 1.13–1.40). COPD was associated with a lower probability of pneumococcal vaccination (OR: 0.51; 95% CI: 0.33–0.79). Conclusions: This study highlights the importance of targeted vaccination campaigns to improve coverage, particularly in regions with lower rates. It also underscores the need for enhanced education and awareness of the benefits of vaccination. Tackling barriers such as vaccine hesitancy and misinformation will be essential for raising vaccination rates and, ultimately, for reducing the burden of cardiovascular disease.

31 October 2021 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
ASAlan R. Sigal
Alan R. Sigal
MAMelisa Antoniolli
Melisa Antoniolli
PSPilar Lopez Santi
Pilar Lopez Santi
NANicolás Aquino
Nicolás Aquino
ELEzequiel Lerech
Ezequiel Lerech
FBFernando Botto
Fernando Botto
Background: The correct management of lipid-lowering treatment is one of the key factors for the reduction of cardiovascular risk in secondary prevention patients. High-dose statins, ezetimibe, and more recently PCSK9 inhibitors (PCSK9i) are the main tools available to meet LDL cholesterol (LDL-C) therapeutic goals in these patients. Despite the overwhelming evidence in their favor, these therapies are greatly underutilized worldwide, with low levels of adherence and therapeutic inertia. In Argentina, there is scarce evidence on the quality of lipid-lowering treatment and the rate of patients in secondary prevention with a controlled lipid profile according to national and international guidelines. Methods: A prospective, multicenter, cross-sectional study including consecutive patients in secondary prevention for cardiovascular events from hospitals of Argentina with a Medical Residency system affiliated to CONAREC, was carried out from March to August 2020. Data was collected on the lipid-lowering treatment received, the reasons behind the non-use of statins in adequate doses and the lipid profile levels in case of having a record from the last 6 months prior to inclusion. Results: Among 1000 consecutive patients included from 24 centers corresponding to 11 provinces, 85.9% was treated with statins, 4.8% with ezetimibe, 2.4% with fibrates, and 13% was without treatment. In the case of patients treated with statin therapy, 67% was receiving high-dose statins (58% of the total number of patients). A total of 509 patients presented LDL-C assessment within the last 6 months. Mean LDL-C was 94 (90.6-97.8) mg/dl, HDL cholesterol 41 (40.7-42.6) mg/dl, and triglycerides 151 (142.9-159.8) mg/dl. In 30% of cases, LDL-C was below the cut-off value of 70 mg/dl and in 16% below 55 mg/ dl. In 37% of patients, LDL-C was >100 mg/dl. Conclusions: In this multicenter secondary prevention study performed in Argentina, just over half of the patients presented high-dose statin treatment, with scarce use of ezetimibe. Undertreatment was reflected in LDL-C values, with more than two-thirds of patients outside the therapeutic range, and therefore far from clinical guideline recommendations. How to cite this article: Sigal AR, Antoniolli M, López Santi P, Aquino N, Lerech E, Botto F, et al. Use of Lipid-Lowering Agents and Therapeutic Goal Achievement in Cardiovascular High-Risk Patients in Argentina. Rev Argent Cardiol 2021;89:373-383 http://dx.doi.org/10.7775/rac.v89.i5.20409